CRESTOR Athero Imaging Head to Head IVUS Study (SATURN)

This study has been completed.
Sponsor:
Collaborator:
The Cleveland Clinic
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00620542
First received: February 6, 2008
Last updated: July 11, 2012
Last verified: July 2012
  Purpose

A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.


Condition Intervention Phase
Coronary Atherosclerosis
Drug: Rosuvastatin
Drug: Atorvastatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV) [ Time Frame: End of study (Week 104) ] [ Designated as safety issue: No ]

    Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as:

    [sum(EEMcsa-LUMENcsa)/sum EEMcsa]*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.



Secondary Outcome Measures:
  • Numbers of Patients Showing Regression in PAV [ Time Frame: End of study (Week 104) ] [ Designated as safety issue: No ]
    Regression defined as a change from baseline in PAV < 0

  • Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV) [ Time Frame: End of study (Week 104) ] [ Designated as safety issue: No ]
    Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.

  • Numbers of Patients Showing Regression in TAV [ Time Frame: End of study (Week 104) ] [ Designated as safety issue: No ]
    Regression defined as a change from baseline in TAV < 0

  • Total Cholesterol Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • LDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Triglycerides Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Non-HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • LDL-C/HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Total Cholesterol/HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Non-HDL-C/HDL-C Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Apolipoprotein B Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Apolipoprotein A-1 Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • Apoliprotein B/Apolipoprotein A-1 Blood Level [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

  • VLDL-C During the 104 Week Treatment Period [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.


Enrollment: 2333
Study Start Date: January 2008
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rosuvastatin 20 mg
Rosuvastatin 20 mg distributed in 2-week run-in period
Drug: Rosuvastatin
capsule, oral, once daily
Other Name: Crestor
Active Comparator: Atorvastatin 40 mg
Atorvastatin 40 mg distributed in 2-week run-in period
Drug: Atorvastatin
capsule, oral, one daily
Other Name: Lipitor
Experimental: Rosuvastatin 40 mg
Rosuvastatin 40 mg distributed in core 2-year study
Drug: Rosuvastatin
capsule, oral, once daily
Other Name: Crestor
Active Comparator: Atorvastatin 80 mg
Atorvastatin 80 mg distributed in core 2-year study
Drug: Atorvastatin
capsule, oral, one daily
Other Name: Lipitor

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical indication for coronary angiography
  • Angiographic evidence of Coronary Artery Disease (CAD), as defined by at least 1 lesion in a native coronary artery that has >20% reduction in lumen diameter by visual estimation
  • Left main coronary artery must have <=50% reduction in lumen diameter by visual estimation
  • LDL-C >100 mg/dL (2.6 mmol/L) for patients with no statin therapy in the past 4 weeks; LDL-C >80mg/dL (2.08mmol/L) for patients on therapy in the past 4 weeks

Exclusion Criteria:

  • Use of certain lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis.
  • Patients who have symptoms consistent with moderate or greater severity of Congestive Heart Failure (CHF).
  • Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00620542

  Hide Study Locations
Locations
United States, Alabama
Research Site
Huntsville, Alabama, United States
United States, California
Research Site
Los Angeles, California, United States
Research Site
Mountain View, California, United States
Research Site
Sacramento, California, United States
Research Site
San Diego, California, United States
Research Site
Santa Rosa, California, United States
Research Site
Torrance, California, United States
United States, Colorado
Research Site
Boulder, Colorado, United States
Research Site
Greeley, Colorado, United States
Research Site
Loveland, Colorado, United States
United States, Connecticut
Research Site
Farmington, Connecticut, United States
United States, District of Columbia
Research Site
Washington, District of Columbia, United States
United States, Florida
Research Site
Clearwater, Florida, United States
Research Site
Ft Lauderdale, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Melbourne, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Sarasota, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Winter Haven, Florida, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
Research Site
Augusta, Georgia, United States
United States, Indiana
Research Site
Elkhart, Indiana, United States
Research Site
Hammond, Indiana, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Merrillville, Indiana, United States
Research Site
Valparaiso, Indiana, United States
United States, Iowa
Research Site
Davenport, Iowa, United States
Research Site
Iowa City, Iowa, United States
Research Site
West Des Moines, Iowa, United States
United States, Kentucky
Research Site
Ashland, Kentucky, United States
Research Site
Lexington, Kentucky, United States
Research Site
Louisville, Kentucky, United States
United States, Louisiana
Research Site
Covington, Louisiana, United States
United States, Maryland
Research Site
Bethesda, Maryland, United States
Research Site
Columbia, Maryland, United States
Research Site
Takoma Park, Maryland, United States
United States, Michigan
Research Site
Bay City, Michigan, United States
Research Site
Grand Blanc, Michigan, United States
Research Site
Kalamazoo, Michigan, United States
Research Site
Midland, Michigan, United States
Research Site
Muskegon, Michigan, United States
Research Site
Petoskey, Michigan, United States
Research Site
Saginaw, Michigan, United States
Research Site
Southfield, Michigan, United States
United States, Minnesota
Research Site
Duluth, Minnesota, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Rochester, Minnesota, United States
Research Site
St Cloud, Minnesota, United States
Research Site
St. Paul, Minnesota, United States
United States, Missouri
Research Site
Columbia, Missouri, United States
Research Site
Kansas City, Missouri, United States
United States, Montana
Research Site
Missoula, Montana, United States
United States, Nebraska
Research Site
Lincoln, Nebraska, United States
Research Site
Omaha, Nebraska, United States
United States, New Jersey
Research Site
New Brunswick, New Jersey, United States
Research Site
Ridgewood, New Jersey, United States
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States
United States, New York
Research Site
Buffalo, New York, United States
Research Site
Johnson City, New York, United States
Research Site
New York, New York, United States
Research Site
Roslyn, New York, United States
Research Site
Williamsville, New York, United States
United States, North Carolina
Research Site
Charlotte, North Carolina, United States
Research Site
Gastonia, North Carolina, United States
Research Site
Greensboro, North Carolina, United States
United States, North Dakota
Research Site
Fargo, North Dakota, United States
United States, Ohio
Research Site
Cincinnati, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Columbus, Ohio, United States
Research Site
Elyria, Ohio, United States
Research Site
Kettering, Ohio, United States
Research Site
Middleburg Heights, Ohio, United States
Research Site
Perrysburg, Ohio, United States
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Tulsa, Oklahoma, United States
United States, Oregon
Research Site
Bend, Oregon, United States
Research Site
Eugene, Oregon, United States
Research Site
Hillsboro, Oregon, United States
United States, Pennsylvania
Research Site
Danville, Pennsylvania, United States
Research Site
Doylestown, Pennsylvania, United States
Research Site
Hershey, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Wormleysburg, Pennsylvania, United States
United States, South Carolina
Research Site
Charleston, South Carolina, United States
United States, Tennessee
Research Site
Chattanooga, Tennessee, United States
Research Site
Germantown, Tennessee, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Memphis, Tennessee, United States
Research Site
Oak Ridge, Tennessee, United States
United States, Texas
Research Site
Dallas, Texas, United States
Research Site
San Antonio, Texas, United States
United States, Virginia
Research Site
Charlottesville, Virginia, United States
United States, Washington
Research Site
Bellevue, Washington, United States
Research Site
Spokane, Washington, United States
Research Site
Tacoma, Washington, United States
Argentina
Research Site
Cap. Fed., Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Buenos Aires, Argentina
Research Site
Rosario, Santa Fe-argentina, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Cordoba, Argentina
Research Site
Corrientes, Argentina
Australia, New South Wales
Research Site
Liverpool, New South Wales, Australia
Research Site
New Lambton Heights, New South Wales, Australia
Australia, Queensland
Research Site
Chermside, Queensland, Australia
Australia, South Australia
Research Site
Adelaide, South Australia, Australia
Australia, Western Australia
Research Site
Perth, Western Australia, Australia
Belgium
Research Site
Aalst, Belgium
Research Site
Brugge, Belgium
Research Site
Brussels, Belgium
Research Site
Charleroi, Belgium
Research Site
Genk, Belgium
Research Site
Leuven, Belgium
Brazil
Research Site
Cariacica, ES, Brazil
Research Site
Vitoria, ES, Brazil
Research Site
Goiania, GO, Brazil
Research Site
Uberlandia, MG, Brazil
Research Site
Cuiaba, MT, Brazil
Research Site
Curitiba, PR, Brazil
Research Site
Ribeirao Preto, SP, Brazil
Research Site
Sao Paulo, SP, Brazil
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada
Research Site
Victoria, British Columbia, Canada
Canada, Manitoba
Research Site
Winnipeg, Manitoba, Canada
Canada, New Brunswick
Research Site
Saint John, New Brunswick, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
Hamilton, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Canada, Quebec
Research Site
Chicoutimi, Quebec, Canada
Research Site
Laval, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Canada, Saskatchewan
Research Site
Saskatoon, Saskatchewan, Canada
Canada
Research Site
Quebec, Canada
France
Research Site
Besancon, France
Research Site
Bron, France
Research Site
Creteil, France
Research Site
Le Plessis-robinson, France
Research Site
Marseille, France
Research Site
Pessac, France
Research Site
Quincy Sous Senart, France
Research Site
Strasbourg, France
Research Site
Toulouse, France
Hungary
Research Site
Budapest, Hungary
Research Site
Szged, Hungary
Italy
Research Site
Arezzo, AR, Italy
Research Site
Sesto San Giovanni, Milano, Italy
Research Site
Milano, MI, Italy
Research Site
Rozzano, MI, Italy
Research Site
Parma, PR, Italy
Research Site
Siena, SI, Italy
Research Site
Udine, UD, Italy
Research Site
Novara, Italy
Research Site
Roma, Italy
Mexico
Research Site
Guadalajara, Jalisco, Mexico
Research Site
Aguascalientes, Mexico
Research Site
D.F, Mexico
Research Site
Monterrey, Mexico
Research Site
Puebla, Mexico
Research Site
Queretaro, Mexico
Research Site
Tijuana, Mexico
Netherlands
Research Site
Alkmaar, Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Breda, Netherlands
Research Site
Eindhoven, Netherlands
Research Site
Enschede, Netherlands
Research Site
Leeuwarden, Netherlands
Research Site
Nieuwegein, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Zwolle, Netherlands
Poland
Research Site
Bialystok, Poland
Research Site
Katowice, Poland
Research Site
Kedzierzyn Kozle, Poland
Research Site
Krakow, Poland
Research Site
Lodz, Poland
Research Site
Poznan, Poland
Research Site
Warszawa, Poland
Research Site
Zabrze, Poland
Russian Federation
Research Site
Krasnogorsk, Moscow Region, Russian Federation
Research Site
Moscow, Russian Federation
Research Site
Saint Petersburg, Russian Federation
Research Site
Tomsk, Russian Federation
Research Site
Tumen, Russian Federation
Spain
Research Site
Malaga, Andalucia, Spain
Research Site
Oviedo, Asturias, Spain
Research Site
Badalona, Cataluna, Spain
Research Site
Barcelona, Cataluna, Spain
Research Site
Madrid, Comunidad de Madrid, Spain
Research Site
Alicante, Comunidad Valenciana, Spain
Sponsors and Collaborators
AstraZeneca
The Cleveland Clinic
Investigators
Principal Investigator: Stephen J Nicholls, MBBS, PhD Cleveland Clinic Foundation, Cardiovascular Medicine
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00620542     History of Changes
Other Study ID Numbers: D356IC00001, 2007-004000-13
Study First Received: February 6, 2008
Results First Received: May 22, 2012
Last Updated: July 11, 2012
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Belgium: Ministry of Social Affairs, Public Health and the Environment
Canada: Health Canada
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Italy: Ministry of Health
Mexico: Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Spain: Spanish Agency of Medicines
United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Coronary artery disease

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Coronary Artery Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Atorvastatin
Rosuvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 19, 2014